| Domain | Established finding | Quantitative evidence | Evidence type | Key limitation |
|---|---|---:|---|---|
| Scope and identifiers | Cardiac, facial, and digital anomalies with developmental delay (CAFDADD), also called TRAF7 syndrome or TRAF7-related neurodevelopmental disorder; MONDO:0032572, OMIM phenotype 618164, ORPHA:592570. The target is the germline developmental syndrome, not TRAF7-mutant meningioma. (pqac-00000000, pqac-00000006) | One associated causal target, **TRAF7**, is recorded for MONDO:0032572. | Aggregated disease resources and literature review | No dedicated ICD-10, ICD-11, or MeSH disease code was identified. |
| Cause and inheritance | Usually caused by a heterozygous germline **TRAF7** missense variant, most often arising de novo; variants cluster in C-terminal WD40 repeats. Rare inherited developmental variants with unaffected carrier parents and postzygotic mosaicism demonstrate exceptions and incomplete penetrance. (pqac-00000001, pqac-00000003, pqac-00000011) | Discovery series: 6/7 confirmed de novo; the seventh lacked paternal testing. In the 45-patient study, 20 amino-acid positions were affected and p.Arg655Gln occurred in 13 index cases. (pqac-00000003, pqac-00000004) | Human genetic cohorts and segregation studies | Penetrance cannot be estimated reliably; inherited variants reported in a congenital-heart-disease study may not reproduce classic CAFDADD fully. |
| Variant spectrum | Recurrent variants include p.Arg655Gln, p.Arg524Trp, p.Phe617Leu, and substitutions at Ser558; most pathogenic syndromic variants alter conserved WD40 residues. The recent cohort added p.Arg653Leu; coiled-coil p.Lys346Glu illustrates a less-certain non-WD40 class. (pqac-00000001, pqac-00000002, pqac-00000003) | Eleven-person series: 8 distinct variants, 7 in WD40 repeats; p.Arg655Gln occurred in 4 unrelated individuals. All were absent from gnomAD v4. (pqac-00000001) | Human sequencing and computational interpretation | Functional validation is unequal across variants; pathogenicity of some coiled-coil variants remains uncertain. |
| Core neurodevelopmental phenotype | Congenital or infantile hypotonia and developmental delay, especially expressive-language and motor delay, are central but variably severe; cognition ranges from normal or near-normal to intellectual disability. (pqac-00000002, pqac-00000024) | Among 68 reported cases: global developmental delay or intellectual disability 90.7%, speech delay 90.4%, motor delay 85.7%, hypotonia 84.8%, autism-spectrum traits 17.7%, seizures 19.0%, and structural neuroimaging abnormalities 79.3%. (pqac-00000030) | Aggregated human case synthesis | Denominators vary by feature; ascertainment and publication bias may inflate frequencies. |
| Craniofacial and sensory phenotype | The recognizable gestalt includes blepharophimosis or ptosis, hypertelorism, abnormal ears and nose, palate or mouth anomalies, micrognathia or retrognathia, and a short or broad neck. Hearing and visual impairment can worsen communication and independence. (pqac-00000005, pqac-00000023) | Among 68 cases: ptosis or blepharophimosis approximately 64–75%, abnormal ears 72.3%, abnormal nose 65.6%, palate or mouth anomalies 74.5%, hearing loss 61.0%, and visual abnormalities 45.5%. (pqac-00000030) | Aggregated human case synthesis | Definitions differ among reports; hearing loss may be conductive, sensorineural, or mixed. |
| Cardiac phenotype | Congenital cardiovascular disease is a major source of early morbidity. Patent ductus arteriosus is characteristic, but septal, valvular, arch, outflow-tract, and complex lesions occur. (pqac-00000004, pqac-00000027) | Among 68 cases: any cardiovascular involvement 85.1%, patent ductus arteriosus 58.2%, valvular or septal defects 53.7%, coarctation 6.0%, pulmonary-artery stenosis 3.0%, and persistent left superior vena cava 4.5%. (pqac-00000030) | Aggregated human case synthesis | The spectrum is broad, and genotype–cardiac-phenotype correlations are not established. |
| Digital and skeletal phenotype | Digital deviation, brachydactyly, syndactyly or other hand and foot anomalies, pectus carinatum, scoliosis, and pes planus or valgus are common. Craniosynostosis, sinus pericranii, and cranio-cervical anomalies define a reported severe cranial subgroup. (pqac-00000005, pqac-00000030) | Among 68 cases: digital anomalies 76.9%, pectus carinatum 45.5%, scoliosis 20.0%, and pes planus or valgus 33.3%. (pqac-00000030) | Human cohorts and case reports | Craniosynostosis and sinus pericranii were reported in few patients and should not be considered universal. |
| Molecular mechanism | The strongest model is altered TRAF7 function, often dominant-negative rather than simple haploinsufficiency. Mutant proteins can heterodimerize with wild-type TRAF7, interact less with IFT57, and disturb ciliogenesis, intraflagellar transport, and neural-crest development. (pqac-00000010, pqac-00000012) | Zebrafish left-right-organizer ciliary beat frequency fell from 50.5 ± 7.14 Hz in controls to 33.47 ± 19.15 Hz in Traf7 morphants, p=6.5×10⁻⁹. (pqac-00000009) | In vitro biochemistry; Xenopus and zebrafish models | The complete chain has not been demonstrated in patient embryonic tissues; knockdown and overexpression models do not precisely reproduce heterozygous human alleles. |
| Vascular signaling mechanism | TRAF7 supports endothelial integrity through the shear-responsive MEKK3–MEK5–ERK5–KLF2 pathway and interactions with SCRIB; disruption may contribute to cardiovascular abnormalities. (pqac-00000015, pqac-00000016) | Endothelial Traf7-null mice: 0% knockout live births versus 25% expected, N=81, χ²=27, p<0.0001; mutants developed fragmented vessels and died around embryonic day 10. (pqac-00000016) | Mouse knockout, embryonic RNA-seq, and HUVEC or HEK293 assays | Complete mouse deletion is embryonically lethal and substantially more severe than heterozygous human missense disease. |
| Diagnosis | Confirmation should use trio exome or genome sequencing, or an appropriate developmental-disorder or congenital-heart-disease panel, followed by ACMG/AMP interpretation and parental segregation testing. Baseline assessment should include echocardiography, development and speech, audiology, ophthalmology, growth and endocrine review, neurologic examination, and targeted brain or spine imaging. (pqac-00000025, pqac-00000026, pqac-00000027) | A representative p.Arg655Gln case was classified pathogenic using PS2, PM1, PM2, PP1, PP2, and PP3. (pqac-00000008) | Human clinical sequencing and case-series recommendations | No validated clinical criteria, biochemical biomarker, enzyme assay, or newborn-screening test exists. |
| Management | Care is supportive and phenotype-directed: cardiology intervention, early physical and occupational therapy, speech and feeding therapy, augmentative communication, hearing and vision treatment, plus orthopedic, neurologic, sleep, and endocrine care. (pqac-00000024, pqac-00000028) | In one 11-person cohort, sleep disorders affected 7/10, hearing loss 11/11, heart defects 10/11, and stature below −2 SD 8/11. (pqac-00000005) | Human case-series recommendations | No disease-modifying drug, genotype-guided pharmacotherapy, gene, RNA, or cell therapy, or relevant interventional trial was identified. |
| Tumor boundary and surveillance | Somatic TRAF7-mutant meningioma is not CAFDADD. A few germline or mosaic syndrome cases with tumors prompted suggestions to consider oncology review after puberty, but cancer-risk magnitude and an evidence-based imaging schedule remain unproven. (pqac-00000023, pqac-00000024) | Reports cited two patients with meningioma and one adult with endometrioid adenocarcinoma; these are isolated observations, not incidence estimates. (pqac-00000023, pqac-00000024) | Human case reports and expert opinion | Routine serial tumor imaging is not an established consensus standard; benefits and harms are unknown. |
| Epidemiology and prognosis gaps | CAFDADD is ultra-rare, but prevalence, incidence, sex ratio, life expectancy, mortality, standardized quality-of-life scores, and validated prognostic biomarkers are unknown. Outcomes vary, and some early hypotonia or delay may improve. (pqac-00000024, pqac-00000029) | The recent synthesis tabulated 68 reported cases; this is a literature case count, not prevalence. (pqac-00000030) | Literature synthesis | Published cases are referral- and publication-biased; long-term adult natural-history data are sparse. |
| Experimental models | Systems include patient fibroblasts, HEK293 and HUVEC assays, Xenopus and zebrafish knockdown or mutant-expression models, and global or endothelial conditional mouse knockouts. They support roles in transcriptional regulation, cilia and IFT, neural crest, heart development, and vascular integrity. (pqac-00000009, pqac-00000011, pqac-00000014, pqac-00000017) | Global Traf7-null mice showed significant genotype depletion by E11.5, N=17 and p=0.0047, and at birth, N=352 and p=0.0001. (pqac-00000017) | Patient-derived cells, in vitro systems, fish and amphibian models, and mouse genetics | No validated heterozygous knock-in model of a recurrent CAFDADD allele or naturally occurring homologous veterinary disease was identified. |


*Table: High-confidence knowledge-base summary for germline TRAF7-related CAFDADD, including clinical frequencies, mechanisms, diagnosis, management, evidence gaps, and models. Somatic TRAF7-mutant meningioma is included only as a disease boundary and limited surveillance context.*